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Abstract
Background: Statins have been proved to be effective in reduction of mortality and morbidity when started in the 
early secondary prevention in stabilized patients after acute coronary syndrome (ACS). The safety and efficacy of statin 
administration directly in the first-line therapy in unstable ACS patients is not clear. The aim of our study was, therefore, 
to assess the effect of statin treatment initiated immediately at hospital admission of patients with ACS.
Methods: The trial was stopped prematurely after enrollment of one hundred and fifty-six patients with ACS that were 
randomized at admission to fluvastatin 80 mg (N = 78) or placebo (N = 78). Study medication was administered 
immediately after randomization and then once daily for 30 days; all patients were then encouraged to continue in 
open-label statin therapy and at the end of one-year follow-up 75% in the fluvastatin group and 78% in the placebo 
group were on statin therapy.
Results: We did not demonstrate any difference between groups in the level of C-reactive protein, interleukin 6, and 
pregnancy-associated plasma protein A on Day 2 and Day 30 (primary endpoint). Fluvastatin-therapy, however, 
significantly reduced one-year occurrence of major adverse cardiovascular events (11.5% vs. 24.4%, odds ratio (OR) 
0.40, 95% CI 0.17-0.95, P = 0.038). This difference was caused mainly by reduction of recurrent symptomatic ischemia 
(7.7% vs. 20.5%, OR 0.32, 95% CI 0.12-0.88, P = 0.037).
Conclusions: This study failed to prove the effect of fluvastatin given as first-line therapy of ACS on serum markers of 
inflammation and plaque instability. Fluvastatin therapy was, however, safe and it may reduce cardiovascular event rate 
that supports immediate use of a statin in patients admitted for ACS.
Trial registration: NCT00171275
Background
Statins (3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors) are cholesterol-lowering drugs, very
effective in the reduction of mortality and non-fatal car-
diovascular events rates in both primary and secondary
prevention of ischemic heart disease. It was, however,
found that statin administration results not only in the
reduction of total- and LDL-cholesterol (statin-induced
blockade of cholesterol-synthesis) but also in a number of
cholesterol-independent effects, known as "pleiotropic"
effects of statins. Development of acute coronary syn-
drome (ACS) involves several pathogenic pathways that
can be inhibited by statins, including cholesterol accumu-
lation in plaque, endothelial dysfunction, activation of
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inflammation and thrombus formation; this fact supports
the idea to use statins also under conditions of ACS.
Recently, several large prospective, controlled clinical tri-
als have been published, showing safety and efficacy of
statins, when administered in stabilized patients early
after ACS [1-3]. An increasing number of observations
demonstrates, however, that statins may play a beneficial
role not only in early secondary prevention but also
directly in the therapy of ACS, i.e. when statin treatment
is started as first-line care in clinically unstable patients.
This therapeutic approach is supported by (i) experimen-
tal studies, showing the protective effect of statins under
the condition of acute ischemia [4-8], (ii) analysis of dif-
ferent registers and trials, demonstrating better prognosis
of statin-treated patients with ACS [9-11], and (iii) small
clinical trials, describing an improvement in some patho-
genic factors and markers as a result of immediate statin
therapy [12-18]. The well-controlled prospective trial
showing the efficacy of statin administration in first-line
therapy of ACS is, however, still lacking. We have
designed, therefore, a prospective, placebo-controlled
trial, testing the hypothesis that statin, when adminis-
tered at admission in patients with ACS, suppresses the
inflammatory burden and improves clinical outcomes.
Methods
Overview
The study design has been published previously [19].
Briefly, the FACS trial is a prospective, multicenter, ran-
domized, double-blind, placebo-controlled study in
patients with ACS. Patients were enrolled between
November 2003 and February 2006 from 5 sites in the
Czech Republic, follow-up was completed in March 2007.
The study complied with the Declaration of Helsinki,
protocol and informed consent form were reviewed and
approved by the multicenter and institutional ethics com-
mittees before study initiation. Eligible patients were ran-
domized to one of two treatment groups immediately
after hospital admission (within one hour). One group
was assigned 80 mg fluvastatin XL once daily, the other
was assigned placebo. The co-primary endoints were the
levels of CRP, IL-6, and PAPP-A/proMBP at days 2 and
30. The combined secondary endpoint was the one-year
occurrence of a major adverse cardiovascular events
(MACE), defined as death, nonfatal myocardial infarction
(MI), recurrent symptomatic myocardial ischemia,
urgent revascularization.
Study population
Patients were eligible for the enrolment if they had ACS
with ST-elevation (rest chest pain less than 12 hours
before admission and ≥ 1 mm ST-segment elevation in 2
or more contiguous leads or new left bundle branch block
on ECG) or non-ST elevation ACS (rest chest pain during
the past 48 hours and ≥ 1 mm ST segment depression or
negative T waves in 2 or more contiguous leads). Exclu-
sion criteria were: concomitant active liver disease or per-
sistent elevation of transaminases more than three times
above the upper limit of normal, history of lipid lowering
t h e r a p y  l e s s  t h a n  3 0  d a y s  b e f o r e  i n d e x  e v e n t ,  k n o w n
allergy for fluvastatin or any present additives in the drug,
disability of oral drug administration, disability of follow-
up, pregnancy or nursing, women of fertile age without
effective contraception, suspicions of muscle disease like
myositis, subjects younger than 18 years, creatine kinase
≥ 5 times of the upper limit of normal range with other
casual explanation than presence of myocardial infarc-
tion.
Study design
Following signed informed consent, blood samples were
taken for examination of serum markers of inflammation
and plaque instability (CRP, IL-6, and PAPP-A/proMBP)
and patients were randomized to fluvastatin 80 mg or
placebo immediately p.o. (within one hour after hospital
admission). Medical history and physical examination,
standard 12-lead ECG, blood lipid profile, and liver func-
tion study were performed as part of routine admission
procedure. Fluvastatin 80 mg/placebo had then been
administered once daily for 30 days. Follow-up examina-
tion of inflammatory markers (CRP, IL-6, and PAPP-A/
proMBP) was performed on day 2 and day 30. Follow-up
visits were scheduled: pre-discharge, and day 30, 90, 180,
360. Blood liver function and creatine kinase tests were
done pre-discharge and at 30-day visits. At the 30-day
visit the lipid profile was also examined and study medi-
cation was withdrawn. All visits included assessment of
the history of cardiovascular events, concomitant medi-
cation and other relevant medical history.
During follow-up, no specific recommendations were
made with respect to diagnostic and therapeutic strategy,
except that other lipid-lowering drugs should be omitted
since randomization until day 30. All management deci-
sions were left to the discretion of each patient's treating
physician.
Laboratory analysis
Serum was prepared immediately after blood sampling
and stored frozen at -70°C until laboratory assessment.
IL-6 in serum was measured by a solid phase, enzyme-
labeled, chemiluminescent sequential immunometric
assay IMMULITE 1000 IL-6 by IMMULITE 1000 immu-
nochemical system (DPC, USA). For the quantitative
determination of C-reactive protein in serum was used a
turbidimetric immunoassay Wako CRP-HS (Wako
Chemicals, Germany); the analysis was performed by
ADVIA 1650 biochemical analyzator (Siemens, USA).Ostadal et al. Trials 2010, 11:61
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The levels of PAPP-A/proMBP were determined by
Kryptor system (Brahms, Germany).
Statistical analysis
Baseline characteristics of the fluvastatin group and pla-
cebo group were compared using t-test, Χ2 test or Fisher
test. Repeated measures ANOVA with three within sub-
ject levels (Day 0, 2, and 30) were used to test the differ-
ences of IL-6, CRP, and PAPP-A between the fluvastatin
group and placebo group. Logarithmic transformation of
continuous data prior to the analysis was used to achieve
normally distributed data and homogeneity of variances
in subgroups. The incidence of cardiovascular events in
the active treatment group was compared with the inci-
dence in the placebo group with an Χ2 test or Fisher test.
For time-to-event analysis a log-rank test was used. Sur-
vival functions were estimated according to the Kaplan-
Meier product-limit method. All the comparisons were
done on intention-to-treat basis and P < .05 was consid-
ered statistically significant.
Safety
The principal safety concerns were hepatic dysfunction
and myopathy. If a patient's serum transaminase levels
were persistently elevated to > 3 times above the upper
limit of normal, the study medication should be discon-
tinued per protocol. Similarly, the study medication
should be stopped if the patient developed muscle pain,
weakness, or tenderness in association with a serum cre-
atine kinase level >10 times above the upper limit of nor-
mal.
Sample size
The trial was originally planned with 1,000 patients to
ensure adequate power to detect significant treatment
benefit of 80 mg fluvastatin with respect to 30-day
decrease of CRP and IL-6 (primary endpoint) and com-
bined secondary endpoint. With 500 patients random-
ized to 80 mg fluvastatin and 500 patients randomized to
placebo the trial had a more than 80% power to detect a
decrease in CRP level by 1.36 mg/L and a decrease in IL-6
Figure 1 Flow chart of subjects included in the trial. Number of patients screened was not determined. All patients completed one-year follow-
up. ACS, acute coronary syndrome.Ostadal et al. Trials 2010, 11:61
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Table 1: Group characteristics.
Fluvastatin
N = 78
Placebo
N = 78
P
Demographical data
Age (years; mean ± SD) 60.9 ± 11.5 63.2 ± 11.3 ns.
Gender ns.
Male 70.5 65.4
Female 29.5 34.6
Weight (kg; mean ± SD) 84.1 ± 13.2 82.7 ± 14.9 ns.
Smoking status ns.
Current smoker 42.3 50.0
Non-smoker 43.6 39.7
Former smoker 14.1 10.3
History
IHD 16.7 25.6 ns.
MI 5.1 10.3 ns.
PCI 1.3 5.1 ns.
CABG 0 1.3 ns.
Diabetes 17.9 20.5 ns.
Hypercholesterolemia 11.5 11.5 ns.
Hypertension 51.3 51.3 ns.
Stroke 3.8 2.6 ns.
PVD 2.6 2.6 ns.
Clinical data
Heart rate (bpm; mean ± SD) 76.1 ± 18.1 72.2 ± 16.5 ns.
SBP (mmHg; mean ± SD) 138.4 ± 29.2 141.1 ± 25.2 ns.
DBP (mmHg; mean ± SD) 81.9 ± 17.4 80.8 ± 18.0 ns.
Acute coronary syndrome type ns.
STE ACS 60.3 69.2
Non-STE ACS 39.7 30.8
Duration of symptoms (Hrs; 
mean ± SD)
10.1 ± 8.9 8.0 ± 5.9 ns.
Killip class ns.
Killip I 88.5 87.2
Killip II 9.0 11.5
Killip III 1.3 0
Killip IV 1.3 1.3
Total cholesterol at admission 
(mmol/L; mean ± SD)
5.5 ± 1.3 5.4 ± 1.1 ns.
Troponin I at admission (μg/L; 
mean ± SD)
14.7 ± 29.1 8.3 ± 14.1 ns.
Peak troponin I (μg/L; mean ± SD) 78.3 ± 110.8 78.7 ± 93.9 ns.
LV ejection fraction (mean ± SD) 48.0 ± 11.4 49.0 ± 10.9 ns.Ostadal et al. Trials 2010, 11:61
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level by 1.09 ng/L; calculations were based on a two-sam-
ple t-test. Estimated combined secondary endpoint rate
was 20%. Based on comparison of proportions with p =
0.05 test significance, the trial had more than 80% power
to detect a decrease by 33% in the combined secondary
endpoint.
Results
The study was stopped prematurely due to slow recruit-
ment rate. A total of one-hundred and fifty-six patients
were randomized and all completed the follow-up; sev-
enty-eight subjects were assigned to each group (Figure
1). We did not capture any unexplained or treatment-
related impaired liver function or myopathy. Fluvastatin
and placebo groups were comparable in the baseline
characteristics including medical history, clinical charac-
teristics, and concomitant medication (Table 1). At day
30, open-label statin therapy was initiated in all patients;
at the end of one-year follow-up, 75% of patients were
treated with statin in the fluvastatin group and 78% in
placebo group (ns.). We did not find any difference
between groups also in the use of acetylsalicylic acid (84%
vs. 87%), ticlopidin or clopidogrel (16% vs. 20%), ACE
inhibitors (77% vs. 72%), and beta-blockers (84% vs. 81%).
We were unable to find significant differences between
the groups in the levels of CRP, IL-6, and PAPP-A (pri-
mary endpoints) (Figure 2). We have observed, however,
significantly lower occurrence of MACE and significantly
longer event-free survival in the fluvastatin group (Table
2, Figure 3). Although the absolute numbers of all single
monitored clinical events were lower in the fluvastatin
group, it reached statistical significance only for recur-
rent symptomatic myocardial ischemia and number of
new hospitalizations (Table 2). At 30 days comparing to
placebo group, fluvastatin decreased the level of total
cholesterol by 24.5% (4.40 ± 0.96 vs. 5.75 ± 1.26 mmol/L,
p < 0.0001) LDL-cholesterol by 29.5% (2.75 ± 0.8 vs. 3.89
± 0.97 mmol/L, p < 0.0001) whereas levels of HDL-cho-
lesterol (1.14 ± 0.32 vs. 1.24 ± 0.32 mmol/L, ns.) and trig-
lycerides (2.18 ± 0.95 vs. 2.09 ± 0.98 mmol/L, ns)
remained unchanged. We did not observe any difference
in creatine kinase (1.58 ± 0.85 vs. 1.44 ± 0.87 μkat/L, ns.)
and liver enzymes (aspartate aminotransferase: 0.47 ±
0.26 vs. 0.44 ± 0.14 μkat/L, ns.; alanine aminotransferase:
0.52 ± 0.24 vs. 0.52 ± 0.27 μkat/L, ns.), all values at 30
days were lower than 3× ULN.
Discussion
The major observation of the present trial is the reduc-
tion of cardiovascular events after administration of flu-
vastatin in first-line therapy of ACS patients treated with
primary PCI or early invasive strategy and according to
the current recommendations despite inability to find any
difference in CRP, IL-6, and PAPP-A levels. The FACS
trial was, however, stopped prematurely and the final
number of patients enrolled is much lower than was
expected. The explanation of the low recruitment rate
can be only speculative: during the enrolment period the
Therapy
Coronary angiography 98.7 98.7 ns.
Coronary intervention 87.2 91.0 ns.
PCI 75.6 87.2 0.098
CABG 11.5 3.8 0.130
ASA 98.7 98.7 ns.
IIb/IIIa inhibitors 5.1 5.1 ns.
UFH/LMWH 82.1 84.6 ns.
Beta-blockers 88.5 88.5 ns.
Diuretics 6.4 16.7 0.077
Clopidogrel 71.8 84.6 0.080
ACE inhibitors 66.7 69.2 ns.
Vyšš í odborná škola 53 52 +1
Values are expressed in per cent or as indicated. IHD, ischemic heart disease; MI, myocardial infarction; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass surgery; PVD, peripheral vascular disease; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; STE, ST-segment elevation on ECG; ACS, acute coronary syndrome; LV, left ventricle; PCI, percutaneous coronary intervention; CABG, 
coronary artery bypass surgery; ASA, acetylsalicylic acid; UFH, unfractionated heparin; LMWH, low-molecular-weight heparin; ACE, 
angiotensin-converting enzyme.
Table 1: Group characteristics. (Continued)Ostadal et al. Trials 2010, 11:61
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results of several large clinical trials with initiation of sta-
tin therapy early after ACS were published leading to
unwillingness of investigators to delay the statin adminis-
tration for 30 days in the placebo group; furthermore,
many physicians initiate statin therapy intuitively earlier
in the less stable ACS patients, still despite insufficient
evidence.
W e were unable to find even a trend to reduction of
CRP and IL-6 levels by fluvastatin. This observation is in
contradiction with several other studies showing
decrease in the various inflammatory markers with early
statin therapy in patients with non-ST-elevation ACS [13-
16,20,21]. This discrepancy can be at least partly
explained by different types and doses of statin used and
also by the recruitment of patients with both types of
ACS in FACS trial leading to increased scattering of
infarct size and pro-inflammatory triggers. Cholesterol-
lowering effect of fluvastatin was, however, fully
expressed and based on the current view on the signaling
pathways participating in the "pleiotropic effects of sta-
tins" it can be supposed that also anti-inflammatory path-
ways were activated but probably not intensively enough
to outweigh the strong pro-inflammatory milieu. Our
observation that PAPP-A levels were not influenced by
fluvastatin therapy is in agreement with the literary data,
showing no [22] or only mild [23] effect of statins on
PAPP-A.
We have found statistically significant, approximately
50% reduction of the major cardiovascular events - the
combined secondary endpoint. This unexpected consid-
erable effect of fluvastatin was apparent across all the
monitored single events including death, non-fatal myo-
cardial infarction, recurrent ischemia, urgent revascular-
ization, or stroke; statistical significance was, however,
reached just in the occurrence of recurrent ischemia and
combined endpoints. There was also significantly better
event-free survival in the fluvastatin group. Moreover,
fluvastatin-treated patients experienced less than half of
new hospitalizations occurring in the placebo group. The
FACS trial had, however, insufficient power to detect a
difference in clinical outcomes and these observations
may be influenced by the low number of participants.
Similar reduction rate after fluvastatin therapy as we have
shown for MACE was also recently reported for cardio-
vascular mortality or myocardial ischemia in the
DECREASE III trial [24]. It can only be speculated that
the beneficial effect of fluvastatin in the FACS trial was
not driven by its anti-inflammatory properties, or was
driven by anti-inflammatory properties not indicated by
the measured biomarkers.
The FACS trial was designed and initiated before the
publication of the large, well-controlled, prospective tri-
als with statin therapy started in stabilized patients earlier
after ACS. From the current point of view, the 30-days
delay in statin administration after ACS in the FACS trial
placebo-arm seems to be very long compared to the max-
imum of ten days in PROVE IT-TIMI 22 trial [2], five days
in A to Z trial [3], or even four days in the MIRACL study
[1] that enrolled, however, only conservatively treated
patients. We cannot, therefore, answer the question
whether there is incremental benefit from the immediate
initiation of statin in the first-line therapy over its post-
ponement for four to ten days. The FACS trial has shown
that therapeutic strategy with administration of fluvasta-
tin at admission in unstable ACS patients might be supe-
rior to the initiation of statins in stabilized patients 30
days after admission.
Conclusions
Up to the best knowledge the FACS trial (Fluvastatin in
the therapy of Acute Coronary Syndrome) is the first ran-
Figure 2 Levels of interleukin 6, CRP, and PAPP-A. D0, day 0; D2, 
day 2; D30, day 30. Panel A: serum levels of interleukin 6. Panel B: serum 
levels of C-reactive protein (CRP). Panel C: serum levels of pregnancy-
associated plasma protein A (PAPP-A). No significant differences be-
tween Fluvastatin group and Placebo group were detected.Ostadal et al. Trials 2010, 11:61
http://www.trialsjournal.com/content/11/1/61
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domized, double blind, placebo-controlled study focused
on the effects of statin administration in the first-line
therapy of acute coronary syndrome. We have shown that
in ACS patients treated with early invasive strategy and
according to the current recommendations for pharma-
cological interventions, fluvastatin therapy started at
admission does not influence serum markers of inflam-
mation and plaque instability, however, it is safe and may
improve clinical outcomes in these patients.
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Table 2: One-year occurrence of major adverse cardiovascular events.
Fluvastatin
N = 78
Placebo
N = 78
OR 95%CI P
Death 1 (1.3) 4 (5.1) 0.24 0.02-2.20 0.37
Nonfatal MI 2 (2.6) 4 (5.1) 0.49 0.08-2.74 0.68
UAP 6 (7.7) 16 (20.5) 0.32 0.11-0.87 0.037
Urgent 
revascularization
6 (7.7) 14 (17.9) 0.38 0.14-1.05 0.09
PCI 5 (6.4) 13 (16.7) 0.34 0.12-1.01 0.08
CABG 1 (1.3) 2 (2.6) 0.49 0.04-5.56 1.0
Stroke 1 (1.3) 3 (3.8) 0.32 0.03-3.19 0.62
New 
hospitalization
14 (17.9) 34 (43.6) 0.28 0.13-0.59 <0.001
Death+MI 3 (3.8) 8 (10.3) 0.35 0.09-1.37 0.21
Death+MI+UAP+
+Urgent 
revascularization
9 (11.5) 19 (24.4) 0.40 0.17-0.95 0.038
Death+MI+UAP+
Stroke++Urgent 
revascularization
10 (12.8) 21 (26.9) 0.40 0.17-0.92 0.044
Values are expressed as No. (%). MI, myocardial infarction; UAP, unstable angina pectoris; PCI, percutaneous coronary intervention; CABG, 
coronary artery bypass surgery
Figure 3 Event-free survival of major adverse cardiovascular 
events. Major adverse cardiovascular events (MACE) were defined as 
death, nonfatal myocardial infarction, symptomatic recurrent isch-
emia, or urgent revascularization.Ostadal et al. Trials 2010, 11:61
http://www.trialsjournal.com/content/11/1/61
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